This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
After an initial rejection in 2020 and a review delay earlier this year, BioMarin’s Roctavian has finally got the FDA go-ahead to introduce a gene therapy for a not-so-rare disorder.
Even without an FDA approval, Roche’s cancer drug Avastin is widely used by doctors to treat certain eye diseases. Even without an FDA approval, Roche’s cancer drug Avastin is widely used by doctors to treat certain eye diseases.
As shortages of drugs like amoxicillin, penicillin, Adderall and certain chemotherapies continue to confound doctors and patients in the U.S., two high-ranking Republican lawmakers are pressing the | As shortages of drugs like amoxicillin, penicillin, Adderall and certain chemotherapies continue to confound doctors and patients in the U.S.,
A new study examined side effect reports of BMCA immunotherapies from the FDA Adverse Event Reporting System, hoping to help inform doctors in their treatment decisions. But these immunotherapies also come with various potentially dangerous side effects. |
Roche has taken another step in its advancement of the blockbuster medicine, scoring an FDA nod to provide it in a prefilled syringe. The 6-mg, single-dose shot will give doctors a simplified, ready-to-use alternative to extracting Vabysmo from a vial.
What doctors described as a “messy” treatment landscape in early-stage non-small cell lung cancer (NSCLC) could get clearer thanks to a first-in-class overall survival win from Merck & Co.’s s Keytruda.
But now, patients and doctors have a new oral option. | FDA has approved US WorldMeds’ Iwilfin—also known as eflornithine—as a new oral maintenance therapy for high-risk neuroblastoma. While existing neuroblastoma treatments can help patients achieve remission, sustaining that remission has proven tricky.
Stimulants are typically the go-to option for doctors prescribing treatments for attention-deficit hyperactivity disorder (ADHD). Tris Pharma has won FDA approval for Onyda XR (clonidine hydrochloride).
SKIMMERS SUMMARY: Jefferies analysts found doctors have shown strong interest in prescribing Aduhelm for about 35% of early-stage Alzheimer’s patients with mild cognitive impairment after surveying 50 U.S. One agency FDA adviser, resigning from his committee post in protest, called it “probably the worst drug approval decision in recent U.S.
Armed with two positive phase 3 trial readouts and the hope that at least one will show a significant patient survival benefit, GSK thinks it has the data to convince doctors and the FDA that the o | Armed with two positive phase 3 trial readouts and the hope that at least one will show a significant patient survival benefit, GSK thinks it has the (..)
To portray patients, mindless people who blindly believe DTC TV ads and rush to their doctor to ask for a product are inaccurate. If the FDA understood consumer behavior like marketers instead of scientists, they would understand how DTC works. This is normal, and the FDA should take note. ” They go online to learn more.
After a full FDA approval last week triggered Medicare coverage of Eisai and Biogen’s Leqembi, doctors are still trying to work out the logistics of testing and reimbursement. But at least two experts remain positive about the drug’s efficacy and safety profile.
With backing from an FDA advisory committee and results from a positive phase 3 trial, respectively, Alnylam and BridgeBio are each on track to enter the blockbuster transthyretin amyloidosis cardi | Alnylam and BridgeBio are each on track to enter the blockbuster transthyretin amyloidosis cardiomyopathy (ATTR-CM) market.
SKIMMERS SUMMARY: Health experts, including those on an external advisory committee to the FDA, are skeptical that Biogen’s drug will even successfully slow the progression of Alzheimer’s after late-stage clinical trials yielded mixed results and are angry the FDA approved the product. Medpage Today.
SUMMARY: The approval of Biogen’s Alzheimer’s drug, after its advisory panel turned it down, begs the Inspector General to open an investigation into the FDA. The FDA gave approval to a medication despite a strong NO vote from their advisory panel of scientific advisers. Where to start? John Carroll, Endpoints.
The FDA needs to study what people do when they see a DTC ad. Today, people don’t see a DTC TV ad and run to their doctor to ask for an Rx. The FDA, in its wisdom, has never studied what patients actually do when they see a DTC TV ad. Still, the gatekeeper continues to be their doctor.
Apellis Pharmaceuticals' Syfovre, after achieving the first FDA approval for advanced eye disease geographic atrophy, has been associated with rare but severe side effects, according to the America | The American Society of Retinal Specialists sent out a note to doctors on Saturday warning of eye inflammation cases in patients who took Syfovre, (..)
Key Points: Trust in the CDC and FDA has decreased dramatically during the COVID-19 pandemic among health care professionals, according to a new WebMD/Medscape poll. doctors surveyed in the same time period, 77% said their trust in the CDC has decreased and 48% said their trust in the FDA has decreased. Out of nearly 450 U.S.
Fitbit collected such information, Faranesh told KHN, as part of a survey submitted to the FDA for clearance of its device. Wearable devices can alert patients to potential health issues that require a visit to the doctor. The challenge is getting to the doctor promptly without needing that maze that has become our healthcare system.
Accelerated Approval was developed in 1992 in response to the HIV/AIDS crisis and has led to expedited drug and biologic approvals in several disease areas across the FDA. Of course, they should, but in the end, it’s going to come down to trust in their doctor and the FDA. Do patients care?
While some doctors have been eager to start prescribing the newly approved drug, others had criticized the FDA for clearing the drug before studies proved it works. ” A physician on STAT News wrote, “the consequences of FDA approval are as disturbing as they are vast.
From treating doctors and providers as partners to viewing your role as an extension to help others in that partnership, he shows how far one can go in the industry when you know how to communicate. Also, I was like, “I probably don’t want to be a doctor because they have to go to school for a long time.” I was an athlete.
Fierce Healthcare reported, “three in 4 Americans leave the doctor confused and dissatisfied for reasons that include disappointment in the level of Q&A they have with their doctor, confusion about their health, and a need to do more research, according to a survey of 1,000 U.S. Of those, 80% turn online to do so.
The old belief is that patients who are interested in new treatments ask their doctor about them. The FDA can be myopic when researching how consumers view and react to DTC. The FDA should be engaging DTG Research to ask the question, “what are people doing when they are interested in an advertised drug?”
GOOD MORNING: The FDA is taking a scientific approach to evaluating direct-to-consumer (DTC) drug advertising, focusing on measuring consumer perceptions of the information presented in ads. Virtually nobody will run to their doctor to ask about a drug they saw on TV without doing research first. ” Uh…no.
SUMMARY: Doctors said they were dissatisfied were marketing emails (46%), telephone sales calls with sales reps (42%), and both webinars and websites (each at 39%) from pharma companies, according to Indegene. One of our tests, one of the most read emails, had a subject line of “new label information for prescribing just FDA approved.”
Jazz’s DTC for Sunosi says “if you have obstructive sleep apnea or narcolepsy and are often tired during the day, ask your doctor if once-daily SUNOSI may be right for you” but what they don’t mention is that obstructive sleep apnea is associated with obesity in more than 60% of cases.
The headlines read “FDA approves obesity drug that helped people cut weight 15%” But buyer beware. My guess is Norvo will heavily discount the product via coupons or cards, but ultimately patients working with their doctor will determine if it’s successful. appeared first on World of DTC Marketing.com.
SUMMARY: The FDA is coming under intense pressure to approve Biogen’s Alzheimer’s drug, but Aaron S. Too many doctors, the data was still questionable. Knopman, a Mayo Clinic neurologist who treats Alzheimer’s patients and is a member of the FDA advisory committee. Washington Post.
But at the same time, 93% of doctors believe mHealth apps can improve patients’ health. 56% of doctors have initiated the use of these tools and 26% of patients have asked about these tools. PWC polled consumers to ask them if they would be willing to use an FDA app or online tool to treat their medical condition.
In the CPG sector there is a new emphasis on omnichannel marketing, but, the FDA is still stuck in the past and won’t allow pharma to get more personal with prescription drug marketing. People trust doctors and having an established though leader write a monthly column, for example, could drive traffic back to your website.
A new feature—a sensor that monitors changes in the heart rate for irregularities that can lead to strokes and heart failure—has just been approved by America’s Food and Drug Administration (FDA). The FDA’s stamp of approval for the Fitbit sensor is a big deal. Google is also giving health records another whirl.
Beyond the Brand Name Dr. Elena Reyes was a doctor'sdoctor. Generics, while FDA-approved, sometimes carried an invisible question mark. Dr. Reyes felt a surge of satisfaction that went beyond the usual doctor-patient success story. Her spotless record and unwavering commitment to their well-being were legendary.
Then, against the advisory panel’s advice, Aduhelm was approved, but insiders within the industry criticized both the FDA and Biogen weren’t sold on the drug or its price tag. Many doctors also became upset at the idea of telling Alzheimer’s patients that the drug didn’t work.
This is why the FDA is going to need to establish a division to monitor digital health products. Pharma has a unique opportunity to link digital health to their products to test them and prove to doctors that they provide better patient outcomes.
Unlike traditional businesses, pharma brands face strict advertising regulations , requiring compliance with FDA guidelines, HIPAA, and Googles healthcare ad policies. Strict ad copy guidelines , including FDA-mandated fair balance requirements. Use FDA-approved language and avoid phrases that suggest guaranteed treatment success.
Doctors can now intervene earlier and more effectively in managing their patients’ care. Charvi Shetty: It started off as a capstone project at UC Berkeley where a UCSF doctor shared the unmet need around monitoring and predicting the onset of respiratory attacks for people suffering from chronic lung conditions like asthma and COPD.
It must convert visitors into leads , provide clear and accurate medical information , and ensure compliance with FDA, HIPAA, and ad platform policies. Avoid misleading claims Always align with FDA-approved language. Request a Free Sample for HCPs or Find a Doctor Near You for patients). Heres how to ensure yours is effective.
Consistently we heard that they like images of real patients or a REAL doctor with one key message communicated. They understand that patient content could be edited to meet FDA requirements, but they like reading others’ experiences managing their health issues. Users spend an average of 5.94 7even: Real patient stories.
It is also important to ensure that the doctors oversee diagnosis. If a doctor makes a mistake when diagnosing and treating your illness, rules establish their responsibility and legal liability. We see new medical data almost every day, some of which the FDA says is questionable. 2wo: Bad Data=Bad Suggestions? 3hree: Oops !
Imagine a time when pharmaceutical ads simply told patients what to ask their doctor. Instead, they actively research symptoms, treatments, and medication reviews before visiting a doctor. Navigating Compliance While personalization and interactivity are powerful, they must align with FDA regulations.
4our: Do they regularly go to their doctor and have a specific HCP they trust? In addition, the FDA seems to be looking at NDAs in terms of REAL outcomes. Pharma DTC marketers should develop personas for their target audience that tells us who they are like: 1ne: Where do they go for medical information online?
Clear Call-to-Action (CTA): Whether encouraging patients to ask their doctors about Jardiance or guiding providers to visit your portal, a strong CTA drives results. FDA Guidelines for DTC Ads: The FDA requires ads to present both benefits and risks equally. What are the FDA requirements for direct-to-consumer ads?
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content